Effects of Mouse Nerve Growth Factor Combined with Low Dose Recombinant Human Erythropoietin on Neurodevelopment in Preterm Infants with Brain Injury
Objective:To investigate the effects of mouse nerve growth factor(mNGF)combined with low dose recombinant human erythropoietin(rhEpo)on neurodevelopment in preterm infants with brain injury.Methods:A total of 200 preterm infants with brain injury,admitted to a hospital from March 2021 to March 2022 were assigned into the control group and the observation group using random number table method,with 100 cases in each group.Both groups were given standard treatment such as nutritional support,electrolyte correction,as well as blood glucose and blood pressure maintenance.The control group was given mouse nerve growth factor for injection in addition to standard treatment,and the observation group was injected intravenously with low dose recombinant human erythropoietin injection(CHO cell)in addition to the control group treatment.The levels of brain injury related factors[neuron-specific enolase(NSE),S100 calcium binding protein β(S100β),8-hydroxydeoxyguanosine(8-OHdG),8-iso-prostaglandin F2α(8-iso-PGF2α)],inflammatory factor[tumor necrosis factor-α(TNF-α),interleukin-18(IL-18),Toll-like receptor 4(TLR4)],neurodevelopmental abnormalities,intelligence grades and adverse reactions were compared between the two groups.Results:Following treatment,the levels of NSE,S100β,8-OHdG and 8-iso-PGF2α decreased in both groups(P<0.05),with the observation group showing lower levels than the control group.The levels of TNF-α,IL-18 and TLR4 decreased in both groups(P<0.05),with the observation group showing lower levels than the control group(P<0.05).The incidences of neurodevelopmental abnormalities with grades≥3 and≥1 were lower in the observation group compared to the control group(P<0.05).The intelligence level of the children in both groups showed an increasing trend(P<0.05),and the increasing trend was more obvious in the observation group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:On that basis of standard treatment,mNGF combined with low dose rhEpo can effectively reduce the levels of brain injury related factors and the rate of neurodevelopmental abnormalities,enhance the intelligence level,and does not increase the risk of adverse reactions.
preterm infantbrain injuryneurodevelopmentmouse nerve growth factorrecombinant human erythropoietinbrain injury related factorsintelligence levelsafety
国家科技期刊平台
NSTL
万方数据
